The Power of Innovation Centres in US Healthcare

By Staff Writer

November 4, 2023

Unveiling the Potential of Healthcare Innovation Centres


A growing trend in US healthcare systems, innovation centres are creating waves in the sector. These centres, which prioritise the quick creation, operationalisation, and assessment of novel innovations—many of which are digital—are transforming the healthcare industry. They are usually developed in response to issues that healthcare systems encounter, with a shared emphasis on problem-solving and real-time healthcare delivery.

These centres focus on three main areas: rapidly testing, assessing, and scaling domestic initiatives; disseminating creative, effective ideas throughout the healthcare system; and creating new solutions and ideas from data, experiences, and activities. Innovation centres can provide excellent, hyperlocal research and quality improvement when they are operating at peak efficiency.



The Success and Sustainability of Innovation Centres


However, it’s estimated that up to 90% of industry innovation centres fail. Despite this, healthcare innovation centres have seen significant growth in the past decade. The key to their success and sustainability lies in how they define their value and success.


Innovation centres often focus on demonstrating value in a creative way, rather than commercialisation of innovations. They add value to their institutions through their projects and innovations. For instance, they may create a decision support tool in the electronic health record to identify patients who smoke upon hospital admission. This not only benefits the patients but also the institution by meeting quality metrics.

These centres also offer value by “failing fast”, spending less money to understand whether a project or innovation will or will not work. This sets them apart from the wider healthcare organisation, which tends to be slower and more cautious.

Centres for healthcare innovation can become sustainable entities within US healthcare institutions. However, they must work effectively with their institutions to define success more broadly than purely financial return on investment. The field needs to develop more robust means of measuring these nonfinancial benefits for long-term success.

Reference url

Recent Posts

datopotamab deruxtecan approval
   

FDA Grants Datopotamab Deruxtecan Approval for HR-Positive Breast Cancer Treatment

💡 *What does the FDA’s latest approval mean for patients with advanced breast cancer?*
Datopotamab deruxtecan (Datroway) has just been approved for treating unresectable or metastatic HR-positive, HER2-negative breast cancer, offering new hope for patients who have already undergone multiple therapies. This breakthrough, stemming from the TROPION-Breast01 trial, showcases significant improvements in progression-free survival rates—a vital advancement in cancer care.

Curious about the implications of this treatment for both healthcare providers and patients? Dive into the full article to learn more!

#SyenzaNews #oncology #HealthcareInnovation

surrogate endpoints guidance
          

Surrogate Endpoints Guidance: New International Report Enhances HTA Practices

🔍 Are surrogate endpoints the key to shaping the future of health technology assessment?

A new report led by NICE reveals standardized guidance for using surrogate endpoints in health economic models, providing clarity and validation tools for HTA decisions. This collaborative effort across multiple global agencies aims to enhance predictions of long-term health benefits from short-term data.

Jump into the article to explore these impactful insights and learn how this guidance is set to improve health technology evaluations!

#SyenzaNews #HealthEconomics #HealthcareInnovation

cervical cancer prevention
    

Cervical Cancer Prevention Strategies: Insights from South African

🌍 Did you know South African women living with HIV face a significantly higher risk of cervical cancer?

Our latest article looks into the perspectives of women and their partners regarding innovative cervical cancer prevention strategies, including the acceptability of the intravaginal 5-fluorouracil (5FU) treatment. It highlights the critical role of education and counseling in improving screening uptake and treatment adherence.

Explore how we can enhance cervical health for vulnerable populations!

#SyenzaNews #globalhealth #oncology #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.